Arcus Biosciences (RCUS) Enterprise Value (2016 - 2026)

Arcus Biosciences' Enterprise Value history runs 11 years deep, the most recent figure standing at -$822.0 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 17.55% year-over-year to -$822.0 million; the TTM figure through Mar 2026 stood at -$822.0 million (up 17.55% YoY), while the FY2025 annual figure was -$981.0 million, changed 0.31% from the prior year.
• Enterprise Value was -$822.0 million for Q1 2026 at Arcus Biosciences, up from -$981.0 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$759.0 million in Q4 2023 to a low of -$1.2 billion in Q1 2022.
• Historically, Enterprise Value has averaged -$968.2 million across 5 years, with a median of -$978.0 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value slumped 102.2% in 2022, then climbed 24.78% in 2023.
• A 5-year view of Enterprise Value shows it stood at -$1.0 billion in 2022, then rose by 24.78% to -$759.0 million in 2023, then declined by 28.85% to -$978.0 million in 2024, then dropped by 0.31% to -$981.0 million in 2025, then gained by 16.21% to -$822.0 million in 2026.
• The last three Enterprise Value figures came in at -$822.0 million (Q1 2026), -$981.0 million (Q4 2025), and -$831.0 million (Q3 2025), per Business Quant data.